ng-nitroarginine methyl ester has been researched along with Bladder Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balarino, NP; Belgorosky, D; Bilbao, ER; Cresta Morgado, PD; Eiján, AM; Langle, YV; Lodillinsky, C; Marino, L; Sandes, EO; Zambrano, M | 1 |
| Alvarez, V; Eiján, AM; Lodillinsky, C; Sandes, E; Umerez, S | 1 |
2 other study(ies) available for ng-nitroarginine methyl ester and Bladder Cancer
| Article | Year |
|---|---|
Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Immunological; BCG Vaccine; Calgranulin B; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Injections, Subcutaneous; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2020 |
Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
Topics: Animals; BCG Vaccine; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Injections, Intralesional; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Spleen; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |